Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Alpine Immune Sciences Inc
(NQ:
ALPN
)
64.60
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Alpine Immune Sciences Inc
< Previous
1
2
3
4
Next >
Alpine Immune Sciences Announces Appointment of Wolfgang Dummer, M.D., Ph.D., as Chief Medical Officer and Grant under Nasdaq Listing Rule 5635(c)
October 04, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Presents First Preclinical Data for Povetacicept in Myasthenia Gravis at the American Neurological Association Annual Meeting
September 12, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences
September 05, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences to Present First Preclinical Data for Povetacicept in Myasthenia Gravis at the American Neurological Association Annual Meeting
September 05, 2023
From
Alpine Immune Sciences, Inc
Via
Business Wire
Alpine Immune Sciences Announces Initiation of Dosing in 240 mg IgA Nephropathy Cohort of Povetacicept Clinical Study (RUBY-3)
August 30, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Announces Appointment of M. Christina Yi as Chief Technology Officer and Grant under Nasdaq Listing Rule 5635(c)
August 22, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Inc. (NASDAQ: ALPN) Records 52-Week High Tuesday Morning
August 15, 2023
Via
Investor Brand Network
Alpine Immune Sciences Reports Second Quarter 2023 Financial Results
August 14, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences to Present Data from RUBY-1, a Phase 1 Study of Povetacicept, at Upcoming Scientific Congresses
May 19, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Reports First Quarter 2023 Financial Results
May 11, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Announces Participation in the Bank of America Securities Healthcare Conference
May 01, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
March 23, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data and Clinical Pharmacokinetic & Pharmacodynamic Modeling at Upcoming Scientific Conferences
March 20, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data at the 2023 American Academy of Dermatology Annual Meeting
March 16, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences to Report Fourth Quarter and Full Year 2022 Financial Results
March 15, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences
February 28, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences to Participate in the SVB Securities Global Biopharma Conference
February 09, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Announces Participation in Fireside Chat at the 5th Annual Evercore ISI HealthCONx Conference
November 22, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2022 Financial Results
November 14, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences to Report Third Quarter 2022 Financial Results
November 07, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Presents Update Of ALPN-303 Phase 1 (RUBY-1) Clinical Data at the American Society of Nephrology Kidney Week 2022 Meeting
November 03, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences to Present ALPN-303 Phase 1 (RUBY-1) Study Data at 2022 American Society of Hematology Annual Meeting & Exposition
November 03, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences to Present ALPN-303 Phase 1 (RUBY-1) Study Data at Upcoming Scientific Conferences
October 26, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Terminates Enrollment of Davoceticept Clinical Studies (NEON-1 and NEON-2)
October 24, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Announces Pricing of $100 Million Public Offering
September 20, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Announces Proposed Public Offering
September 20, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences to Highlight Clinical Updates on Autoimmune and Immuno-Oncology Programs at Inaugural R&D Day
September 12, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Announces Participation in September Investor Conferences
September 06, 2022
From
Alpine Immune Sciences Inc.
Via
Business Wire
Alpine Immune Sciences Announces R&D Day to Provide Clinical Updates on Wholly-Owned Programs ALPN-303 and Davoceticept
August 30, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Announces Inducement Grant to Andrew S. Sandler, M.D. Under Nasdaq Listing Rule 5635(c)
August 18, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.